DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K. et al.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: A phase 1 dose-escalation study.
Lancet Oncol 2017;
18: 1512-22
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.